| Literature DB >> 28531105 |
Oliver J Taylor1, Mikayla O Thatcher2, Sheryl T Carr3, Jonathan L Gibbs4, Annie M Trumbull5, Mitchell E Harrison6, Duane R Winden7, Mackenzie J Pearson8, Trevor S Tippetts9, William L Holland10, Paul R Reynolds11, Benjamin T Bikman12.
Abstract
We have previously found that cigarette smoke disrupts metabolic function, in part, by increasing muscle ceramide accrual. To further our understanding of this, we sought to determine the role of the cytokine high-mobility group box 1 (HMGB1), which is increased with smoke exposure, in smoke-induced muscle metabolic perturbations. To test this theory, we determined HMGB1 from lungs of human smokers, as well as from lung cells from mice exposed to cigarette smoke. We also treated cells and mice directly with HMGB1, in the presence or absence of myriocin, an inhibitor of serine palmitoyltransferase, the rate-limiting enzyme in ceramide biosynthesis. Outcomes included assessments of insulin resistance and muscle mitochondrial function. HMGB1 was significantly increased in both human lungs and rodent alveolar macrophages. Further testing revealed that HMGB1 treatment elicited a widespread increase in ceramide species and reduction in myotube mitochondrial respiration, an increase in reactive oxygen species, and reduced insulin-stimulated Akt phosphorylation. Inhibition of ceramide biosynthesis with myriocin was protective. In mice, by comparing treatments of HMGB1 injections with or without myriocin, we found that HMGB1 injections resulted in increased muscle ceramides, especially C16 and C24, which were necessary for reduced muscle mitochondrial respiration and compromised insulin and glucose tolerance. In conclusion, HMGB1 may be a necessary intermediate in the ceramide-dependent metabolic consequences of cigarette smoke exposure.Entities:
Keywords: ceramides; cigarette smoke; high-mobility group box 1 (HMGB1); mitochondrial bioenergetics
Mesh:
Substances:
Year: 2017 PMID: 28531105 PMCID: PMC5455007 DOI: 10.3390/ijms18051099
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Human pulmonary biopsies from normal nonsmoker lung (A) (n = 7); smoker without diagnosed emphysema (B) (n = 15); and smoker with diagnosed emphysema (C) (n = 14) were immunohistochemically stained for high-mobility group box 1 (HMGB1). Qualitatively, HMGB1 was markedly increased in the lungs of smokers (B,C) compared to nonsmokers. Images are representative and imaged at original magnification of 63× and 4–5 random fields were evaluated by blinded individuals as to the type of sample.
Figure 2Cigarette smoke exposure increases HMGB1 in muscle. The 12–14-week-old male C57Bl6 mice were exposed to cigarette smoke (CS) or room air (RA) daily for 6 days. HMGB1 was then determined from serum (A) (n = 6); HMGB1 protein was also measured from cell culture medium of primary macrophages treated with PBS or cigarette smoke extract (CSE) (B) (n = 5) via ELISA or Western blot from alveolar macrophages from mice following smoke exposure (C) (n = 6). *** p < 0.001; * p < 0.05 for CS/CSE vs. RA.
Figure 3HMGB1 increases ceramide levels and biosynthetic genes in muscle cells. Following treatment (or no treatment; CON) with HMGB1 alone (H; 10 μg), HMGB1 with myriocin (H + M; 10 µM) or myriocin alone (Myr; 10 μM), murine myotubes were tested for ceramide levels (A) (n = 8); Expression of genes involved in ceramide biosynthesis was measured following HMGB1 treatment (B) (n = 4). * p < 0.05 vs. CON. # p < 0.05 vs. HMGB1.
Figure 4HMGB1 disrupts mitochondrial function and insulin signaling in a ceramide-dependent manner. Cells were incubated in control (CON) conditions, or with HMGB1 alone (10 μg), HMGB1 with myriocin (H + M; 10 µM) or myriocin alone (Myr; 10 μM). To measure mitochondrial respiration (A) (n = 4–5); cells were treated with: GM: Glutamate (10 mM) + Malate (2 mM); GM: + ADP (2.5 mM); GMS: + Succinate (10 mM); GMS: + FCCP (0.05 μM). Respiratory control ratio was determined by GM/GM (B) (n = 4–5); Production of reactive oxygen species (C) (n = 3) was determined via dichlorofluorescin (DCF) assay. * p < 0.05 vs. CON. Insulin signaling (D) (n = 4) via Akt phosphorylation (Ser-473) was determined by treating cells with insulin (100 nM) for 10 min prior to lysing. * p < 0.05 vs. CON. # p < 0.05 vs. HMGB1.
Figure 5HMGB1 increases muscle ceramides. The 12–14-week old male mice received daily injections of placebo (CON), HMGB1 (1 µg/day), myriocin alone (MYR; 3 µg/kg thrice weekly), or myriocin + HMGB1 for 14 days (n = 6). Following the treatment period, ceramides were analyzed from soleus. * p < 0.05 vs. CON. # p < 0.05 vs. HMGB1.
Figure 6HMGB1 disrupts metabolic function in mice. Following 14 days of placebo (CON), HMGB1 (1 µg/day), myriocin alone (MYR; 3 µg/kg thrice weekly), or myriocin + HMGB1 for 14 days (n = 6), intraperitoneal glucose (A) and insulin (B) tolerance tests were performed on 12–14-wk old male mice (n = 6). Mitochondrial respiration was determined on harvested red gastrocnemius (C) (n = 6) and respiratory control ratio was determined by GM/GM (D) (n = 6). * p < 0.05 vs. CON. # p < 0.05 vs. HMGB1.